University of Barcelona / IBMB-CSIC

designed "celiacase," a recombinant enzyme active at gastric pH that degrades gluten immunogenic peptides — including the 33-mer fragment from wheat alpha-gliadin — synergistically with pepsin before they reach the duodenum, reducing intestinal atrophy, inflammation, antibody response and dysbiosis in mouse models;…

Country
Spain
Coverage
CNEUUS
food-alt-protein
Regulatorsemafda

Verifiable facts

FactValueSource
AffiliationMolecular Biology Institute of Barcelona (IBMB-CSIC), Institute for Research in Nutrition and Food Safety (INSA-UB), and Faculty of Pharmacy and Food Sciences at the University of Barcelona (UB)ibmb.csic.es · rdcsic.dicat.csic.es · pcb.ub.edu
Research focusDesign and testing of recombinant enzymes (celiacase) for the degradation of gluten immunogenic peptides in coeliac disease managementibmb.csic.es · link.springer.com · esrf.fr · pcb.ub.edu
FacilityProteolysis Lab (IBMB-CSIC)ibmb.csic.es
FacilityESRF (European Synchrotron Radiation Facility) beamline ID23-1Aesrf.fr
GrantAgencia Estatal de Investigación, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, Ministry of Science and Innovation, and Catalan Coeliac Associationdoi.org · pubmed.ncbi.nlm.nih.gov · rdcsic.dicat.csic.es
Principal staffF. Xavier Gomis-Rüth (IBMB-CSIC), Francisco J. Pérez-Cano (INSA-UB), Marina Girbal-González (INSA-UB), Arturo Rodríguez-Banqueri (IBMB-CSIC)ibmb.csic.es · pcb.ub.edu

Independent sources: doi.org · esrf.fr · ibmb.csic.es · link.springer.com · pcb.ub.edu · pubmed.ncbi.nlm.nih.gov · rdcsic.dicat.csic.es

Technologies
NameClusterRisk
Enzymatic therapy for celiacfood-alt-proteinMedium

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.